The objective of this work was to develop a long-acting form of the lipidated peptide semaglutide that can be administered to humans once-monthly. Semaglutide was attached to hydrogel microspheres by a cleavable linker with an expected in vivo release half-life of about 1 mo. After a single subcutaneous dose, the pharmacokinetic parameters of released semaglutide and bodyweight loss were determined in mice, and results were used to estimate the dosing and pharmacokinetics of the released semaglutide in humans. The in vivo half-life of released semaglutide was ~36 d, and a single dose in diet-induced obese mice resulted in a lean-sparing body weight loss of 20% over 1 mo, statistically the same as semaglutide dosed twice daily. Simulations indicated the microsphere-semaglutide would permit once-monthly administration in humans; moreover, it could maintain the therapeutic minimum concentration (C) of once-weekly semaglutide with only 75% of the once-weekly maximum concentration (C), a feature that could reduce adverse side effects or allow higher dosing. The same approach should enable the conversion of other lipidated peptides from once-weekly to once-monthly administration.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11588095 | PMC |
| http://dx.doi.org/10.1073/pnas.2415815121 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Glucagon-like Peptide-1 Receptor Agonists in the Management of Diabetic Retinopathy.
Int Ophthalmol Clin
January 2025
Cullen Eye Institute, Baylor College of Medicine, Houston, TX.
Glucagon-like peptide-1 (GLP-1) receptor agonists are a family of drugs, most well known by the third-generation once-weekly subcutaneous semaglutide, that act on the incretin pathway of metabolic, hormonal signaling to modulate pancreatic insulin release, gastric emptying, energy intake, and subjective feelings of satiety. This class of drugs' efficacy and safety in the treatment of type 2 diabetes and obesity have been demonstrated across multiple large randomized controlled trials. These data have propelled GLP-1 receptor agonists to ubiquity in diabetic management and weight loss therapy, leading them to be frequently encountered in ophthalmic practice.
View Article and Find Full Text PDFExploring the Therapeutic Potential of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in Polycystic Ovary Syndrome.
Cureus
November 2024
Obstetrics and Gynecology, Mount Sinai Medical Center, Miami Beach, USA.
Polycystic ovary syndrome (PCOS) is a complex endocrine disorder affecting women of reproductive age and is characterized by hormonal imbalances, insulin resistance, and reproductive dysfunctions. Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RAs) are primarily used in diabetes management to enhance insulin release by stimulating GLP-1 receptors in the pancreas. The search strategy included randomized trials on the management of PCOS symptoms with GLP-1 RAs alone or in combination with other medications; meta-analyses, literature reviews, or case reports were excluded.
View Article and Find Full Text PDFIncretin-based therapy: a new horizon in diabetes management.
J Diabetes Metab Disord
December 2024
Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA USA.
Diabetes mellitus, a metabolic syndrome characterized by hyperglycemia and insulin dysfunction, often leads to serious complications such as neuropathy, nephropathy, retinopathy, and cardiovascular disease. Incretins, gut peptide hormones released post-nutrient intake, have shown promising therapeutic effects on these complications due to their wide-ranging biological impacts on various body systems. This review focuses on the role of incretin-based therapies, particularly Glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, in managing diabetes and its complications.
View Article and Find Full Text PDFAn analysis of national news coverage of semaglutide for weight loss.
J Am Pharm Assoc (2003)
November 2024
Background: Glucagon-like peptide 1 (GLP-1) agonists like semaglutide have risen significantly in use in recent years as a therapeutic option for the management of obesity. Popular media serves as an information source for many patients, and depending on the content, may influence how a patient views a particular therapy.
Objective: To describe the content of online/print news articles published about semaglutide for weight loss.
Semaglutide promotes the transition of microglia from M1 to M2 type to reduce brain inflammation in APP/PS1/tau mice.
Neuroscience
December 2024
Department of Physiology, Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, Shanxi Province, PR China. Electronic address:
A growing number of studies show that the diabetes drug Semaglutide is neuroprotective in Alzheimer's disease (AD) animal models, but its mode of action is not fully understood. In order to explore the mechanism of Semaglutide, 7-month-old APP/PS1/tau transgenic (3xTg) mice and wild-type (WT) mice were randomly divided into four groups: control group (WT + PBS), AD model group (3xTg + PBS), Semaglutide control group (WT + Semaglutide) and Semaglutide treatment group (3xTg + Semaglutide). Semaglutide (25 nmol/kg) or PBS was administered intraperitoneally once every two days for 30 days, followed by behavioral and molecular experiments.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!